Canigen DHPPi Lyophilisate for Suspension for Injection for Dogs
Active ingredients: Canine adenovirus, Canine distemper virus, Canine parainfluenza virus, Canine parvovirus
Form
Injection
Species
Manufacturer
Intervet International B.V.
VMD MA No.
06376/4107
What it's used for
viral excretion due to canine adenovirus type 1 infection. To prevent mortality, clinical signs and viral excretion following canine parvovirus infection....
Full indications, dosage and side effects ↓The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.
Paying less for Canine adenovirus + Canine d...
-
1
Ask your vet for a written prescription
They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
-
2
Fill it at a registered online retailer
The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.
Done — we'll email you when prices land.
Prescription required
Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.
Canigen DHPPi Lyophilisate for Suspension for Injection for Dogs — SPC Details
Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.
signs and viral excretion following canine parvovirus infection. To reduce clinical signs
and viral excretion caused by canine parainfluenza virus infection and to reduce
clinical signs of respiratory disease and viral excretion following adenovirus type 2
infection.
Onset of immunity:
Canine distemper virus, canine adenovirus and canine parvovirus vaccine
components: 1 week.
Canine parainfluenza virus vaccine component: 4 weeks.
Duration of immunity:
Canine distemper virus, canine adenovirus and canine parvovirus vaccine
components: 3 years.
The duration of immunity for the canine parainfluenza virus component has not been
demonstrated, but an anamnestic response is produced in dogs given a revaccination
one year after basic vaccination. Annual revaccination with the canine parainfluenza
virus vaccine component is recommended.
listed in section 3.8.
Avoid contamination of vaccine with traces of chemical sterilising agents. Do not use
chemicals such as disinfectant or spirit to disinfect the skin prior to inoculation.
Maternal antibodies can negatively interfere with the efficacy of a vaccine. Strict
adherence to the vaccination programme is therefore recommended.
Vaccination programme:
Primary vaccinations:
A single injection should establish active immunity to canine distemper, infectious
canine hepatitis and disease caused by canine parvovirus infection in dogs of 10
weeks of age or older.
Where earlier protection is required a first dose may be given to puppies from 6 weeks
of age, but because maternally derived passive antibody can interfere with the
response to vaccination a final dose at 10 weeks of age or older is generally
recommended.
For an optimal response to the parainfluenza component, animals should be
vaccinated twice, 2 – 4 weeks apart with the final vaccination at 10 weeks of age or
more.
If the initial primary course dose of Canigen DHPPi is delayed to 10 weeks of age or
older, a single dose of Canigen Pi at 12 weeks of age or older should suffice to
establish immunity for this component.
Revaccination:
It is recommended that dogs be revaccinated with canine distemper virus, canine
adenovirus and canine parvovirus every 3 years and against canine parainfluenza
virus every year.
It was not possible to produce clinical signs of kennel cough by parainfluenza
challenge in adult dogs and duration of immunity could not therefore be demonstrated,
but an anamnestic response was seen in dogs given a booster one year after primary
vaccination. Revaccination against parainfluenza is recommended prior to exposure to
high risk environments (such as kennelling, showing or mixing with dogs of unknown
vaccination history).
Reconstituted product: off-pink or pink coloured suspension.
Very rare
(<1 animal / 10,000 animals treated,
including isolated reports):
Injection site swelling.
Elevated temperature.
Hypersensitivity reaction (e.g. lethargy,
facial oedema, pruritus, vomiting or
diarrhoea).
1
Small and transient (≤ 5 cm), which can occasionally be firm and painful on palpation.
Any such swelling will either have disappeared or be clearly diminished by 14 days
post-vaccination.
Transient.
Such reaction may evolve to a more severe condition (anaphylaxis), which may be
life-threatening with additional signs like ataxia, dyspnoea, tremor and collapse. If such
reactions occur, appropriate treatment is recommended.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.
The vaccine may not be effective in dogs incubating the disease at the time of
vaccination.
A good immune response is reliant on the reaction of an immunogenic agent and a
fully competent immune system. Immunocompetence of the animal may be
compromised by a variety of factors including poor health, nutritional status, genetic
factors, concurrent drug therapy and stress.
The immunogenicity of the vaccine antigen will be reduced by poor storage or
inappropriate administration.
The vaccine has been proved to be of benefit against virulent challenge in the
presence of maternal antibody levels to CDV, CAV2, CPV and CPi that are likely to be
encountered under field conditions.
Experience has shown that the maternal antibody status of pups within a litter varies
greatly, and reliance should not be placed on serological examination of the bitch
alone.
Special precautions for safe use in the target species:
Animals that have received a corresponding anti-serum or immunosuppressive drugs
should not be vaccinated until an interval of at least 4 weeks has elapsed.
Vaccinated dogs may excrete the parvovirus vaccine strain at very low levels up to 8
days following vaccination. However, there is no evidence of any reversion to virulence
of the vaccine strain and therefore no need to separate unvaccinated dogs from
contact with recently vaccinated dogs.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
In the case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician.
Special precautions for the protection of the environment:
Not applicable.
vaccine can be mixed and administered with the inactivated vaccines in the Canigen
range against canine leptospirosis caused by all or some of the following serovars: L.
interrogans serogroup Canicola serovar Canicola, L. serogroup
Icterohaemorrhagiae serovar Copenhageni, L. interrogans serogroup Australis serovar
Bratislava, and L. serogroup Grippotyphosa serovar Bananal/Liangguang.
The product information of the relevant Canigen vaccines should be consulted before
administration of the mixed product. When mixed with Canigen leptospirosis vaccines
at annual revaccination, it has been established that there is no interference with the
anamnestic response induced by the injectable canine parainfluenza virus component.
After administration with one of the leptospirosis vaccines, a mild and transient
increase in body temperature 1 °C) may occur for a few days after vaccination, with
some pups showing less activity and/or a reduced appetite. A small transient swelling
(≤ 4 cm), which can occasionally be firm and painful on palpation, may be observed at
the site of injection. Any such swelling will either have disappeared or be clearly
diminished by 14 days post-vaccination.
After mixed administration of an overdose of this vaccine and an overdose of the
leptospirosis vaccines in the Canigen range, transient local reactions such as diffuse
to firm swellings from 1 to 5 cm in diameter may be observed, usually these will persist
no longer than 5 weeks, however some may take a little longer to completely
disappear.
Safety data and efficacy data for the canine distemper virus, canine adenovirus and
canine parvovirus components of this vaccine are available which demonstrate that
this vaccine can be administered at the same time but not mixed with the inactivated
vaccine in the Canigen range against bronchiseptica.
When this vaccine is administered in association with the inactivated vaccine in the
Canigen range against Bordetella bronchiseptica, the demonstrated antibody response
data for the live canine parainfluenza component of this vaccine are the same as when
this vaccine is administered alone.
When this vaccine is used with any of the other Canigen vaccines referred to above,
the minimum vaccination age for each vaccine must be taken into account such that at
the time of vaccination, the dogs are at or older than the oldest minimum vaccination
age for the individual vaccines.
Safety and efficacy data are available which demonstrate that this vaccine can be
administered on the same day with solvent or the vaccine in the Canigen range
containing inactivated rabies virus strain Pasteur RIV. These can be used to
reconstitute this freeze-dried vaccine.
No information is available on the compatibility of this vaccine when used with any
other veterinary medicinal product except the products mentioned above. A decision to
use this vaccine before or after any other veterinary medicinal product therefore needs
to be made on a case by case basis.
Do not freeze.
Protect from light.
Avoid prolonged or repetitive exposure to high ambient temperatures following
withdrawal from the refrigerator prior to use. In hot summer conditions vaccine potency
can be severely reduced within a few hours.
This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.
Medication costs adding up?
Pet insurance can cover prescription medications. Find the right policy for your pet.
Related Conditions
Other Products Containing Canine adenovirus
These products share the same active ingredient and may be suitable alternatives. Always consult your vet.
Canigen DHP Lyophilisate and Solvent for Suspension for Injection for Dogs
POM-VIntervet International B.V.
Canixin DHPPi Lyophilisate and Solvent for Suspension for Injection for Dogs
POM-VVirbac
Canixin DHPPi Lyophilisate and Solvent for Suspension for Injection for Dogs
POM-VVirbac
Canixin DHPPi/L
POM-VVIRBAC
CANIXIN DHPPi/L Lyophilisate and Suspension for Suspension for Injection for Dogs
POM-VVirbac
Eurican DAP Lyophilisate and Solvent for Suspension for Injection
POM-VBoehringer Ingelheim Vetmedica GmbH
Alternative options to consider
Retailers we earn a commission from. It costs you nothing and never changes what we show.
The Pharm Pet Co. — Pet Pharmacy
UK online pet pharmacy. Flea, worm, prescription medications, supplements and pet food. Save vs vet prices.
Pet Care at Pharmacy2U
The UK's largest online pharmacy. Pet wormers, flea treatments, dental and joint care. Free delivery on orders over £30.
VetBox Flea & Worm Protection for Dogs
Vet-founded monthly parasite subscription. Flea, tick and worm protection delivered to your door. Founded by Dr Will Woodley, protecting 30,000+ pets.
We may earn a small commission if you purchase through these links, at no extra cost to you.
Related Medications
Aftopur AlSap
POM-VFoot-and-mouth disease virus
Aftopur AlSap
POM-VFoot-and-mouth disease virus
Aftopur DOE
POM-VFoot-and-mouth disease virus
Aftopur DOE
POM-VFoot-and-mouth disease virus
Alpha Ject Micro 1 PD Emulsion for Injection for Atlantic Salmon
POM-VSalmon pancreas disease virus
Alpha Ject Micro 1 PD Emulsion for Injection for Atlantic Salmon
POM-VSalmon pancreas disease virus
Find cheaper vets near you
Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.